Aptevo Therapeutics Net Income
| APVO Stock | USD 6.01 0.40 6.24% |
As of the 5th of February, Aptevo Therapeutics shows the Standard Deviation of 6.52, mean deviation of 4.6, and Risk Adjusted Performance of (0.23). Aptevo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Aptevo Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 0.1222 | Earnings Share 7.4 K | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -27.7 M | -29.1 M | |
| Net Loss | -27.7 M | -29.1 M | |
| Net Income Applicable To Common Shares | 9.2 M | 9.7 M | |
| Net Loss | -28.3 K | -29.7 K | |
| Net Income Per E B T | 0.84 | 0.66 |
Aptevo | Net Income | Build AI portfolio with Aptevo Stock |
Evaluating Aptevo Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Aptevo Therapeutics's fundamental strength.
Latest Aptevo Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Aptevo Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Aptevo Therapeutics financial statement analysis. It represents the amount of money remaining after all of Aptevo Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Aptevo Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aptevo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (24.13 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Aptevo Net Income Regression Statistics
| Arithmetic Mean | (39,004,263) | |
| Coefficient Of Variation | (72.64) | |
| Mean Deviation | 21,593,368 | |
| Median | (44,698,000) | |
| Standard Deviation | 28,332,850 | |
| Sample Variance | 802.8T | |
| Range | 120.4M | |
| R-Value | 0.52 | |
| Mean Square Error | 621.8T | |
| R-Squared | 0.27 | |
| Significance | 0.03 | |
| Slope | 2,935,842 | |
| Total Sum of Squares | 12844T |
Aptevo Net Income History
Other Fundumenentals of Aptevo Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Aptevo Therapeutics Net Income component correlations
Aptevo Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Aptevo Therapeutics is extremely important. It helps to project a fair market value of Aptevo Stock properly, considering its historical fundamentals such as Net Income. Since Aptevo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aptevo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aptevo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Aptevo diversify its offerings? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aptevo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Aptevo Therapeutics requires distinguishing between market price and book value, where the latter reflects Aptevo's accounting equity. The concept of intrinsic value - what Aptevo Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aptevo Therapeutics' price substantially above or below its fundamental value.
Understanding that Aptevo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aptevo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aptevo Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Aptevo Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aptevo Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aptevo Therapeutics.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Aptevo Therapeutics on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Aptevo Therapeutics or generate 0.0% return on investment in Aptevo Therapeutics over 90 days. Aptevo Therapeutics is related to or competes with Kiora Pharmaceuticals, HCW Biologics, Abpro Holdings, Matinas BioPharma, In8bio, Biocardia, and Eterna Therapeutics. Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for... More
Aptevo Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aptevo Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aptevo Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.32) | |||
| Maximum Drawdown | 43.37 | |||
| Value At Risk | (10.34) | |||
| Potential Upside | 6.67 |
Aptevo Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aptevo Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aptevo Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aptevo Therapeutics historical prices to predict the future Aptevo Therapeutics' volatility.| Risk Adjusted Performance | (0.23) | |||
| Jensen Alpha | (2.10) | |||
| Total Risk Alpha | (2.38) | |||
| Treynor Ratio | (2.55) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aptevo Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aptevo Therapeutics February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.23) | |||
| Market Risk Adjusted Performance | (2.54) | |||
| Mean Deviation | 4.6 | |||
| Coefficient Of Variation | (315.89) | |||
| Standard Deviation | 6.52 | |||
| Variance | 42.48 | |||
| Information Ratio | (0.32) | |||
| Jensen Alpha | (2.10) | |||
| Total Risk Alpha | (2.38) | |||
| Treynor Ratio | (2.55) | |||
| Maximum Drawdown | 43.37 | |||
| Value At Risk | (10.34) | |||
| Potential Upside | 6.67 | |||
| Skewness | (1.72) | |||
| Kurtosis | 8.6 |
Aptevo Therapeutics Backtested Returns
Aptevo Therapeutics secures Sharpe Ratio (or Efficiency) of -0.32, which signifies that the company had a -0.32 % return per unit of risk over the last 3 months. Aptevo Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Aptevo Therapeutics' Standard Deviation of 6.52, mean deviation of 4.6, and Risk Adjusted Performance of (0.23) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.81, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aptevo Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aptevo Therapeutics is expected to be smaller as well. At this point, Aptevo Therapeutics has a negative expected return of -2.15%. Please make sure to confirm Aptevo Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Aptevo Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.74 |
Good predictability
Aptevo Therapeutics has good predictability. Overlapping area represents the amount of predictability between Aptevo Therapeutics time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aptevo Therapeutics price movement. The serial correlation of 0.74 indicates that around 74.0% of current Aptevo Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.74 | |
| Spearman Rank Test | 0.67 | |
| Residual Average | 0.0 | |
| Price Variance | 9.44 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Aptevo Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Aptevo Therapeutics reported net income of (24.13 Million). This is 107.07% lower than that of the Biotechnology sector and 134.45% lower than that of the Health Care industry. The net income for all United States stocks is 104.23% higher than that of the company.
Aptevo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aptevo Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aptevo Therapeutics could also be used in its relative valuation, which is a method of valuing Aptevo Therapeutics by comparing valuation metrics of similar companies.Aptevo Therapeutics is currently under evaluation in net income category among its peers.
Aptevo Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aptevo Therapeutics from analyzing Aptevo Therapeutics' financial statements. These drivers represent accounts that assess Aptevo Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aptevo Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 64.7M | 20.8M | 3.9M | 2.1M | 2.4M | 2.3M | |
| Enterprise Value | 36.4M | 7.7M | (7.6M) | (2.0M) | (2.3M) | (2.2M) |
Aptevo Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aptevo Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aptevo Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aptevo Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aptevo Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Aptevo Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aptevo Therapeutics' value.| Shares | Clear Street Llc. | 2025-06-30 | 0.0 | Virtu Financial Llc | 2025-03-31 | 0.0 | Hrt Financial Llc | 2025-03-31 | 0.0 | Advisor Group Holdings, Inc. | 2025-06-30 | 3.2 K | Tower Research Capital Llc | 2025-06-30 | 1.2 K | Sbi Securities Co Ltd | 2025-06-30 | 588 | Bank Of America Corp | 2025-06-30 | 3.0 | Blackrock Inc | 2025-06-30 | 1.0 | Ubs Group Ag | 2025-03-31 | 0.0 | Center For Financial Planning Inc | 2025-03-31 | 0.0 | Diadema Partners Lp | 2025-03-31 | 0.0 |
Aptevo Fundamentals
| Return On Equity | -2.43 | ||||
| Return On Asset | -0.79 | ||||
| Current Valuation | (9.55 M) | ||||
| Shares Outstanding | 1.56 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 4.40 % | ||||
| Number Of Shares Shorted | 219.92 K | ||||
| Price To Earning | 2.48 X | ||||
| Price To Book | 0.38 X | ||||
| Price To Sales | 1.61 X | ||||
| Gross Profit | 345 K | ||||
| EBITDA | (23.78 M) | ||||
| Net Income | (24.13 M) | ||||
| Cash And Equivalents | 29.43 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 4.63 M | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 4.48 X | ||||
| Book Value Per Share | 22.67 X | ||||
| Cash Flow From Operations | (23.79 M) | ||||
| Short Ratio | 0.55 X | ||||
| Earnings Per Share | 7,445 X | ||||
| Target Price | 378.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 1.48 | ||||
| Market Capitalization | 10.01 M | ||||
| Total Asset | 15.59 M | ||||
| Retained Earnings | (247.58 M) | ||||
| Working Capital | 4.45 M | ||||
| Current Asset | 71.41 M | ||||
| Current Liabilities | 19.54 M | ||||
| Net Asset | 15.59 M |
About Aptevo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aptevo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aptevo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aptevo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Aptevo Stock
Moving against Aptevo Stock
| 0.91 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.73 | ENGN | enGene Holdings Common | PairCorr |
| 0.69 | DSGN | Design Therapeutics | PairCorr |
| 0.68 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.68 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Will Biotechnology sector continue expanding? Could Aptevo diversify its offerings? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aptevo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Aptevo Therapeutics requires distinguishing between market price and book value, where the latter reflects Aptevo's accounting equity. The concept of intrinsic value - what Aptevo Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aptevo Therapeutics' price substantially above or below its fundamental value.
Understanding that Aptevo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aptevo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aptevo Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.